The standard CRC regimen, 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX), was evaluated and shown that Tregs were significantly reduced in those with high baseline levels, with no change in relative proportions of CD4, CD8, or NK cells (79, 80). This evidence concerns the gene CD4 and colorectal carcinoma.